Traditionally, the most specific biomarkers of AD, such as positron emission tomography with amyloid or tau tracers, and cerebrospinal fluid biomarker analysis, remain concentrated in research institutes and specialized tertiary hospitals, making them inaccessible to most of the population, particularly in rural areas and in low- and middle-income countries [50,51]. This evidence concerns the gene MAPT and Alzheimer disease.